EuroBiotech: More Articles of Note

> Manchester Science Partnerships (MSP) unveiled its plans for the Alderley Park campus vacated by AstraZeneca ($AZN). The aim of the £30 million ($45 million), three-year redevelopment program is to create 1.5 million square feet of leasable space and better equip the campus to serve multiple occupants. MSP released artist impressions of a four-story laboratory that is among the first targets for the program. Release

> Cellectis (EPA:ALCLS) teamed up with Dutch service provider ModiQuest Research. The French CAR-T player will work with ModiQuest to generate monoclonal antibodies against its targets. ModiQuest set up shop in 2004 and uses antibodies derived from mice, rats, rabbits, chickens, llamas and humans to help clients hit their therapeutic targets. Release

> Israeli-American biotech Chiasma said it plans to relocate its U.S. headquarters to a bigger office in Newton or Cambridge, MA, in the coming months. Chiasma is flush with cash at the moment after closing a $70 million (€66 million) Series E round. Boston Business Journal

Midatech Pharma (AIM:MTPH) revealed it is working on a short-term project with a large pharma firm. The 6-month program will assess whether the gold-nanoparticle and oral strip technologies used by MidaSol--a joint venture between Midatech and MonoSol Rx--can deliver insulin. The deal includes an upfront payment and milestones. Proactive Investors

Targovax ($TRVX) began preparing to expand the Phase I/II trial of its pancreatic cancer immunotherapy. The move will add up to 13 patients to the study--which has already met its primary endpoints--to gather more information on the optimal treatment regimen and its safety profile. Targovax will use the data in deliberations about the design of an upcoming proof-of-concept trial. Release

MorEx wrapped up the first part of a trial of its radiation enhancer MTL-005 in patients with advanced carcinoma of the head and neck. The safety review panel saw no dose-limiting toxicities in the data and cleared MorEx to proceed to the next stage of the study. MorEx will now step up the ambition of the trial, pivoting from just aiming for palliative care to trying to cure the carcinoma. The British company is also looking for a partner. Release

BioLineRx ($BLRX) raised $28.75 million (€27 million) through an offering of its American Depository Shares. The Israeli biotech priced the shares well below the amount they were trading for prior to the announcement, causing its stock to slide in its home territory and on the U.S. exchange. Turning to U.S. investors for money--as BioLineRx has done in the past--leaves the company with $60 million in cash. Release | Globes

Nordic Nanovector priced its IPO. The Norwegian biotech is aiming to raise up to NOK 876 million ($108 million) when it goes public on its local stock exchange. Nordic Nanovector will use the money to continue clinical development of Betalutin--its antibody-radionuclide-conjugate lead candidate--in follicular lymphoma and diffuse large B-cell lymphoma. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.